Capricor Therapeutics, Inc. news
- Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform
- Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. Avat Brings Over 25 Years of Business and Commercial Strategy Experience to Capricor
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based thera
- Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States
- Upfront Payment of $30 Million Received in 1 st Quarter Strengthens Cash Position and Extends Cash Runway
- Positive Phase 2 Results Published in The Lancet Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
- Pivotal Phase 3 Trial Expecting to Begin Enrolling Patients th
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May
Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Ca
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics, announced today that its Phase 2, INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 as a potential treatment opt
- One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients
- Data Sets Stage for Pivotal Phase 3 HOPE-3 Clinical Trial
CAP-1002 Cell Therapy Programs
- Pivotal Phase 3, HOPE-3 Trial Initiation Underway-
- Entered Exclusive Partnership with Nippon Shinyaku for Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in United States-
- Capricor to Receive Upfront Payment of $30 Million with Additional Milestone Payments of up to $705 Million-
- Phase 2 INSPIRE Top-Line Data Expected by End of Fir